Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 2 boards, counting each seat separately. Longest: Halozyme Therapeutics Inc., 3 years.
Halozyme Therapeutics Inc.
Director
Nautilus Biotechnology Inc.
Director
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Nautilus Biotechnology Inc. June 13, 202497.8%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 16, 2026 | Halozyme Therapeutics Inc. | Open-market sale | −3,100 | $106.13 | $329,009 |
| Sep 16, 2026 | Halozyme Therapeutics Inc. | Open-market sale | −3,000 | $106.83 | $320,484 |
| Sep 16, 2026 | Halozyme Therapeutics Inc. | Open-market sale | −8,896 | $108.04 | $961,124 |
| Sep 16, 2026 | Halozyme Therapeutics Inc. | Open-market sale | −4,000 | $108.99 | $435,964 |
| May 5, 2026 | Halozyme Therapeutics Inc. | Grant or award | +3,796 | — | — |
| May 1, 2025 | Halozyme Therapeutics Inc. | Grant or award | +4,165 | — | — |
| Aug 14, 2024 | Halozyme Therapeutics Inc. | Open-market sale | −9,881 | $57.70 | $570,134 |
| Aug 13, 2024 | Halozyme Therapeutics Inc. | Open-market sale | −10,000 | $56.19 | $561,900 |
| Aug 12, 2024 | Halozyme Therapeutics Inc. | Open-market sale | −10,000 | $55.72 | $557,200 |
| Jun 12, 2024 | Halozyme Therapeutics Inc. | Open-market sale | −10,000 | $50.62 | $506,200 |
| Jun 11, 2024 | Halozyme Therapeutics Inc. | Open-market sale | −10,000 | $50.01 | $500,100 |
| Apr 25, 2024 | Halozyme Therapeutics Inc. | Grant or award | +6,501 | — | — |
| May 5, 2023 | Halozyme Therapeutics Inc. | Grant or award | +8,065 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.